brand logo

Am Fam Physician. 2019;99(1):55

Clinical Question

What are the most effective drug therapies for hirsutism?

Bottom Line

Combination oral contraceptive pills (OCPs) are an excellent treatment option for women desiring medical therapy for hirsutism. Based on this meta-analysis, an accompanying practice guideline recommends adding an antiandrogen, such as finasteride (Propecia), if there is an inadequate response within six months. The guideline also recommends avoiding monotherapy with an antiandrogen and avoiding the use of insulin sensitizers such as metformin because of the inconsistency of the evidence (J Clin Endocrinol Metab. 2018;103(4):1233–1257). (Level of Evidence = 1a–)

Synopsis

This is a network meta-analysis from the Mayo Clinic Evidence-Based Practice Center. It was methodologically sound, although the risks of comparing apples to bananas, and oranges to bananas, and using the results to extrapolate about apples to oranges has inherent limitations. After a search of three databases, the authors found 43 randomized trials that evaluated a treatment for hirsutism compared with either placebo or another active treatment. Eight studies compared different OCPs with one another and three studies provided qualitative data, leaving 32 for the network meta-analysis. The median age of participants was approximately 25 years, and the studies included women with a fairly wide range of hirsutism severity. Most trials were believed to be at high risk of bias due to inadequate allocation concealment during randomization, a failure to mask participants and/or outcome assessors, and financial conflicts of interest of the investigators. The strongest evidence comes from direct comparisons. Regarding comparisons with placebo, metformin was studied in nine trials (albeit with heterogeneity); finasteride in three trials; flutamide (Eulexin) in two; and OCPs, spironolactone, troglitazone, and OCP plus flut-amide in one each. The network meta-analysis concluded that there was the strongest evidence for efficacy of combination estrogen-progestin OCPs, antiandrogens (primarily for women who are using long-acting contraception or who have been sterilized), and metformin. All OCPs appeared to be similarly effective.

Study design: Meta-analysis (randomized controlled trials)

Funding source: Foundation

Setting: Various (meta-analysis)

Reference:BarrionuevoPNabhanMAltayarOet alTreatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab2018;103(4):1258–1264.

Editor's Note: Dr. Mark H. Ebell is Deputy Editor for Evidence-Based Medicine in AFP and cofounder and Editor-in-Chief of Essential Evidence Plus, published by Wiley-Blackwell, Inc.

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.

To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.

This series is coordinated by Sumi Sexton, MD, editor-in-chief.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

Continue Reading


More in AFP

More in Pubmed

Copyright © 2019 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.